Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Irish Medicines Board Grants Merrion Pharmaceuticals New Facility License, Allows Manufacturing For Clinical Trials

By Pharmaceutical Processing | July 29, 2010

Further reinforcing its successful growth in providing easily absorbed oral pills that are generally given by injection, Merrion Pharmaceuticals plc, a pharmaceutical development company, today announced that its new state-of-the-art facility in Citywest, CO Dublin has been licensed under the EU Clinical Directive for Investigational Medicinal Products. Inspections conducted by the Irish Medicines Board confirmed the quality, safety and efficacy of medicines developed at the facility.

Designed to most efficiently develop new drug products and manufacture for clinical development, the 30,000 sq. ft pharmaceutical facility was acquired by Merrion in July 2009. The purchase provided the Company with much-needed additional research and development space for the company to undertake its existing workload and to initiate new collaborations and products. 

The Irish Medicines Board is responsible for monitoring the quality of medicines by conducting inspections at sites of manufacture and distribution of medicines and by random sampling of products both pre and post authorization. The IMB ensures regulation throughout Ireland and the European Union.

“The granting of this license is another important milestone for Merrion,” said John Lynch, CEO, Merrion Pharmaceuticals, “as it allows us to manufacture for clinical trials. We have a great track record of high-quality standards in rapidly developing and manufacturing products based on our GIPET® technology. The IMB license for our Citywest facility will allow us to expand the number of products we can develop for ourselves and for partners.”

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE